Acyclovir News and Research

RSS

Acyclovir is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV.

Ethosomes may be effective carrier system for transdermal delivery

Ethosomes are ethanolic nanovesicles that possess abundant amount of ethanol in its core which provides fluidity to the lipid bilayers and thus by this effect, improves the delivery of molecules into the deep skin layers.

7 Oct 2016

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

Common herpes drug Valacyclovir decreases HIV-1 levels

Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.

16 Mar 2015

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma SA, an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea.

2 Apr 2014

Risk factors linked to death may be reversible in severe encephalitis patients

People with severe encephalitis - inflammation of the brain - are much more likely to die if they develop severe swelling in the brain, intractable seizures or low blood platelet counts, regardless of the cause of their illness, according to new Johns Hopkins research.

21 Aug 2013

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

BioAlliance Pharma SA, a Company dedicated to the development of orphan oncology products and supportive care products, has presented the results of the pharmacokinetic and pharmacodynamic study on Sitavig at the 10th EADV spring symposium (European Academy of Dermatology and Venereology) in Cracow (Poland) on May 24, 2013.

28 May 2013

JPIDS releases consensus statement of Sentinel Project on Pediatric Drug-Resistant Tuberculosis

The Journal of the Pediatric Infectious Diseases Society today released its June issue, which includes a consensus statement of the global Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

22 May 2013

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.

4 Apr 2013

A new strategy to prevent herpes virus infections

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing infections due to the highly common herpes simplex viruses, the microbes responsible for causing genital herpes (herpes simplex virus 2) and cold sores (herpes simplex virus 1).

26 Mar 2013

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

25 Jul 2012

Study confirms condom use reduces risk of HIV infection by 78%

The level of HIV-1 in the blood of an HIV-infected partner is the single most important factor influencing risk of sexual transmission to an uninfected partner, according to a multinational study of heterosexual couples in sub-Saharan Africa.

12 Jan 2012

HSV1 drugs could slow progression of Alzheimer's disease

Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer's disease (AD), a new study shows.

From The University of Manchester 18 Oct 2011

Valeant to acquire rights relating to Elidel and Xerese from Meda

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.

30 Jun 2011

Valeant, Meda partner for life cycle opportunities for Elidel and Xerese

Meda and Valeant have entered into a collaboration agreement. Meda has out-licensed exclusive rights for Elidel and Xerese to Valeant for the U.S., Canada and Mexico. The parties will collaborate on life cycle opportunities for both products.

30 Jun 2011

African genital herpes strains are more infectious than the U.S. virus

Strains of genital herpes in Africa are far more virulent than those in the United States, researchers at Harvard Medical School report, a striking insight into a common disease with important implications for preventing HIV transmission in a region staggered by the HIV/AIDS epidemic.

15 Apr 2011

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.

1 Mar 2011

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases.

23 Nov 2010